PhIIIAdjuvV940mRNA4157+PembrolizumabVSAdjuvPlacebo+Pembrow/ResectStageII IIIAIIIB N2NonsmallCellLung
Hari Keshava
- IRB INITIAL APPROVAL
trials found matching your search:
Displaying 20 of 51 Results
Outcomes w/ mpMRI Compared to Diagnostic TURBT in Pts w/ Suspected Muscle-Invasive Bladder Cancer
Nataliya Mar
- OPEN TO ACCRUAL
PhI BL-B01D1 in Subjects with Metastatic or Unresectable Non-Small Cell Lung Cancer
Sai-Hong Ou
- OPEN TO ACCRUAL
NeoadDurvalumab+ChemothVSChemotheAlonw/MammaPrintHormRece+HumaEpidGrowFacRecepNegStagII-IIIBreastCa
Ritesh Parajuli
- OPEN TO ACCRUAL
A Biobehavioral Intervention to Reduce Adverse Outcomes in Young Adult Testicular Cancer Survivors
Michael A Hoyt
- OPEN TO ACCRUAL
PhIII HighFiveTrial Five Fraction Rad for HighRisk Prostate Ca
Steven Neema Seyedin
- OPEN TO ACCRUAL
Pilot to Assess Diversity of Gut Microbiome in Met NSCLC in Correlation to Tx & Adverse Effects
Misako Nagasaka
- OPEN TO ACCRUAL
PhIIIMirvetuximabSoravtansineCombW/BevacizumabVSBevacizumab PaW/FrA+After2ndLine PlatinumChemo +Bev
Krishnansu Tewari
- OPEN TO ACCRUAL
PhI/IIIBemarituzumab + Chemo &Nivo vsChemo & Nivo in Subj w/Prev Untreat Adv Gastric & GEC w/FGFR2b
Farshid Dayyani
- OPEN TO ACCRUAL
EMBER-4: PhIII Imlunestrant vs EndoThera Pts Recieved 2to5 years Adj Endocrine Ther ER+HER2 Recurren
Ritesh Parajuli
- OPEN TO ACCRUAL
Ph IIIb Durvalumab Combo w/Chemotherapy for First Line Tx for Pts w/Advanced Biliary Tract Cancers
Farshid Dayyani
- OPEN TO ACCRUAL
PhIII Olvi-Vec Platinum-doublet ChemotherapyBevacizumab Compatedw/PlatinumDoublet Chemo&Bevacizumab
Krishnansu Tewari
- OPEN TO ACCRUAL
Ph II Study of ZN-c3 in High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Ca
Krishnansu Tewari
- OPEN TO ACCRUAL
Assessing the Predictive Capability of ctDNA as a Screening Tool for Ovarian Cancer
Jill Tseng
- OPEN TO ACCRUAL
Ph II Novel Immunomod as Monotherapy & Combo w/Anticancer Agents in Pts w/ Adv Hepatobiliary Cancer
Farshid Dayyani
- OPEN TO ACCRUAL
PhII M1774 in Refr SPOP-mutant Prostate Ca
Arash Rezazadeh Kalebasty
- OPEN TO ACCRUAL
PhIII Trial PerioperativeVSAdj Chemothe Resectable PancreaticCa
Jennifer Brooke Valerin
- OPEN TO ACCRUAL
Randomized PhIII Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Meta Colorectal Ca
Farshid Dayyani
- OPEN TO ACCRUAL
Pragmatic RandomPhIII Trial Eval Total AblativeThe Pa w/Limited MetaColoRecCa Eval Rad Ablation&Surg
Oliver Eng
- OPEN TO ACCRUAL
PhIII Inavolisib+FulvestrantVSAlpelisib+Fulvestrant Pa w/HormoneRecep+ HER2- PIK3CA BreastCa
Ritesh Parajuli
- OPEN TO ACCRUAL